A new treatment targeting the tumor environment in advanced prostate cancer
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression
This study is testing a new treatment for advanced prostate cancer that targets specific cells in the tumor's surroundings to help stop the cancer from growing and becoming resistant to current therapies, offering hope for patients who may not respond to traditional hormone treatments anymore.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11015837 on NIH RePORTER |
What this research studies
This research investigates a novel therapy designed to disrupt the tumor-stroma interaction that fuels the progression of lethal prostate cancer. It focuses on targeting specific cells in the tumor microenvironment that contribute to cancer growth and resistance to existing treatments. By using a specially designed small molecule that activates in the presence of tumor-associated fibroblasts, the therapy aims to reduce the cancer's ability to thrive and evade treatment. Patients may benefit from a new approach that does not rely on traditional hormone therapies, which often become ineffective over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are men with advanced prostate cancer who have developed resistance to hormone therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for patients with advanced prostate cancer that is resistant to current therapies.
How similar studies have performed: Other research has shown promise in targeting the tumor microenvironment, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Brennen, William Nathaniel — Johns Hopkins University
- Study coordinator: Brennen, William Nathaniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.